- Home
- BOLT vs IGC Comparison
BOLT vs IGC Comparison
Compare BOLT & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLT
- IGC
- Stock Information
- Founded
- BOLT 2015
- IGC 2005
- Country
- BOLT United States
- IGC United States
- Employees
- BOLT N/A
- IGC N/A
- Industry
- BOLT Biotechnology: Pharmaceutical Preparations
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- BOLT Health Care
- IGC Health Care
- Exchange
- BOLT Nasdaq
- IGC Nasdaq
- Market Cap
- BOLT 16.8M
- IGC 20.2M
- IPO Year
- BOLT 2021
- IGC N/A
- Fundamental
- Price
- BOLT $5.69
- IGC $0.31
- Analyst Decision
- BOLT Buy
- IGC Strong Buy
- Analyst Count
- BOLT 3
- IGC 2
- Target Price
- BOLT $50.00
- IGC $3.88
- AVG Volume (30 Days)
- BOLT 23.5K
- IGC 219.7K
- Earning Date
- BOLT 08-12-2025
- IGC 08-07-2025
- Dividend Yield
- BOLT N/A
- IGC N/A
- EPS Growth
- BOLT N/A
- IGC N/A
- EPS
- BOLT N/A
- IGC N/A
- Revenue
- BOLT $3,638,000.00
- IGC $1,236,000.00
- Revenue This Year
- BOLT N/A
- IGC N/A
- Revenue Next Year
- BOLT $24.14
- IGC $16.45
- P/E Ratio
- BOLT N/A
- IGC N/A
- Revenue Growth
- BOLT N/A
- IGC 1.65
- 52 Week Low
- BOLT $5.20
- IGC $0.25
- 52 Week High
- BOLT $15.60
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- BOLT 42.69
- IGC 52.79
- Support Level
- BOLT $5.36
- IGC $0.30
- Resistance Level
- BOLT $6.07
- IGC $0.32
- Average True Range (ATR)
- BOLT 0.44
- IGC 0.01
- MACD
- BOLT -0.01
- IGC 0.00
- Stochastic Oscillator
- BOLT 25.58
- IGC 33.33
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.